Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Sponsor: Merck Sharp & Dohme LLC